Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$542.62−4.41 (-0.81%)
Close on Nov 12, 2026Market cap $137.53BP/E 31.6Yield –
Vertex Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Vertex Pharmaceuticals's cash was $7.85B at Jun 30, 2026. For fiscal 2025 it was $6.61B, up 8.0% from the year before. Over ten years it grew 24.9% a year on average. The highest annual figure on record is $11.22B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.61B | +8.0% |
| FY2024 | Dec 31, 2024 | $6.12B | -45.5% |
| FY2023 | Dec 31, 2023 | $11.22B | +4.1% |
| FY2022 | Dec 31, 2022 | $10.78B | +43.2% |
| FY2021 | Dec 31, 2021 | $7.52B | +13.0% |
| FY2020 | Dec 31, 2020 | $6.66B | +74.9% |
| FY2019 | Dec 31, 2019 | $3.81B | +20.2% |
| FY2018 | Dec 31, 2018 | $3.17B | +51.7% |
| FY2017 | Dec 31, 2017 | $2.09B | +76.4% |
| FY2016 | Dec 31, 2016 | $1.18B | +65.6% |
| FY2015 | Dec 31, 2015 | $714.77M | +14.3% |
| FY2014 | Dec 31, 2014 | $625.26M | +9.8% |
| FY2013 | Dec 31, 2013 | $569.30M | +16.3% |
| FY2012 | Dec 31, 2012 | $489.41M | +3.0% |
| FY2011 | Dec 31, 2011 | $475.32M | +95.4% |
| FY2010 | Dec 31, 2010 | $243.20M | -45.6% |
| FY2009 | Dec 31, 2009 | $446.66M | +14.8% |
| FY2008 | Dec 31, 2008 | $389.12M | +9.4% |
| FY2007 | Dec 31, 2007 | $355.66M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.85B | +23.0% |
| Q1 FY2026 | Mar 31, 2026 | $7.25B | +16.9% |
| Q4 FY2025 | Dec 31, 2025 | $6.61B | +8.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.29B | -3.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.38B | +10.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.20B | -39.0% |
| Q4 FY2024 | Dec 31, 2024 | $6.12B | -45.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.52B | -45.3% |
| Q2 FY2024 | Jun 30, 2024 | $5.80B | -48.4% |
| Q1 FY2024 | Mar 31, 2024 | $10.17B | -2.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.22B | +4.1% |
| Q3 FY2023 | Sep 30, 2023 | $11.93B | +22.1% |
| Q2 FY2023 | Jun 30, 2023 | $11.24B | +21.4% |
| Q1 FY2023 | Mar 31, 2023 | $10.41B | +26.4% |
| Q4 FY2022 | Dec 31, 2022 | $10.78B | +43.2% |
| Q3 FY2022 | Sep 30, 2022 | $9.77B | +40.4% |
| Q2 FY2022 | Jun 30, 2022 | $9.25B | +37.9% |
| Q1 FY2022 | Mar 31, 2022 | $8.24B | +19.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.52B | +13.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.96B | +13.2% |
| Q2 FY2021 | Jun 30, 2021 | $6.71B | +23.1% |
| Q1 FY2021 | Mar 31, 2021 | $6.92B | +65.2% |
| Q4 FY2020 | Dec 31, 2020 | $6.66B | +74.9% |
| Q3 FY2020 | Sep 30, 2020 | $6.15B | +53.9% |
| Q2 FY2020 | Jun 30, 2020 | $5.45B | +38.0% |
| Q1 FY2020 | Mar 31, 2020 | $4.19B | +20.5% |
| Q4 FY2019 | Dec 31, 2019 | $3.81B | +20.2% |
| Q3 FY2019 | Sep 30, 2019 | $4.00B | +30.8% |
| Q2 FY2019 | Jun 30, 2019 | $3.95B | +42.8% |
| Q1 FY2019 | Mar 31, 2019 | $3.48B | +40.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.17B | +51.7% |
| Q3 FY2018 | Sep 30, 2018 | $3.06B | +120.6% |
| Q2 FY2018 | Jun 30, 2018 | $2.77B | +126.3% |
| Q1 FY2018 | Mar 31, 2018 | $2.48B | +146.8% |
| Q4 FY2017 | Dec 31, 2017 | $2.09B | +76.4% |
| Q3 FY2017 | Sep 30, 2017 | $1.38B | +92.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.22B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.00B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.18B | – |
| Q3 FY2016 | Sep 30, 2016 | $719.69M | – |
See a number that looks wrong?